What’s in a name? Problems, facts and controversies regarding neurological eponyms

Abstract

The use of eponyms in neurology remains controversial, and important questions have been raised about their appropriateness. Different approaches have been taken, with some eponyms being excluded, others replaced, and new ones being created. An example is Hallervorden-Spatz syndrome, which has been replaced by neurodegeneration with brain iron accuulatium (NBIA). Amiothoplic lateral sclerosys (ALS), for which the eponym is Charcot’s disease, has been replaced in the USA by Lou Gehrig’s disease. Guillain-Barré syndrome (GBS) is an eponym that is still the subject of controversy, and various different names are associated with it. Finally,restless legs syndrome (RLS), which was for years known as Ekbom’s syndrome, has been rechristened as RLS/Willis-Ekbom syndrome.

Abordagens fisioterapêuticas na síndrome de Guillain-Barré: uma revisão integrativa

“…A síndrome de Guilain-Barré (SGB) é considerada uma doença autoimune, uma forma de polirradiculoneuropatia desmielinizante inflamatória aguda, tendo como configuração clínica mais comum, a paralisia flácida ascendente, a qual leva à ausência dos reflexos miotáticos (TEIVE et al, 2016). Na maioria das vezes essa patologia é decorrente de doenças virais e bacterianas agudas que afetam principalmente o Sistema Nervoso Periférico (SNP), sendo o citomegalovírus, Campylobacterjejuni e Epstein-Barr os vírus mais comumente associados a esta patologia (ORSINI,2012;MONTINI et al, 2016).…”